The Developing Medicines through Open Science (DMOS) program provides up to $1,600,000 per project to support preclinical drug development in areas of pharmaceutical market failure
The Developing Medicines through Open Science (DMOS) program provides up to $1,600,000 per project to support preclinical drug development in areas of pharmaceutical market failure, such as rare diseases and antimicrobial resistance. Eligible activities include research projects within Technology Readiness Levels (TRLs) 2-6 that involve at least one Canadian SME and adhere to the open science policy.
D’autres programmes dans le même domaine.
1871
Natural Resources Canada (NRCan)
500 Global
500 Global
